Precision Oncology Medicine: The Clinical Relevance of Patient-Specific Biomarkers Used to Optimize Cancer Treatment
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Precision Oncology Medicine: The Clinical Relevance of Patient-Specific Biomarkers Used to Optimize Cancer Treatment
Authors
Keywords
-
Journal
JOURNAL OF CLINICAL PHARMACOLOGY
Volume 56, Issue 12, Pages 1484-1499
Publisher
Wiley
Online
2016-05-21
DOI
10.1002/jcph.765
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Osimertinib: First Global Approval
- (2016) Sarah L. Greig DRUGS
- Analytical Validation and Application of a Targeted Next-Generation Sequencing Mutation-Detection Assay for Use in Treatment Assignment in the NCI-MPACT Trial
- (2016) Chih-Jian Lih et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- ALK Protein Analysis by IHC Staining after Recent Regulatory Changes: A Comparison of Two Widely Used Approaches, Revision of the Literature, and a New Testing Algorithm
- (2016) Antonio Marchetti et al. Journal of Thoracic Oncology
- Alectinib Approved for ALK+ Lung Cancer
- (2016) Cancer Discovery
- Decision-making impact on adjuvant chemotherapy allocation in early node-negative breast cancer with a 21-gene assay: systematic review and meta-analysis
- (2015) Federico Augustovski et al. BREAST CANCER RESEARCH AND TREATMENT
- Mechanisms of lapatinib resistance in HER2-driven breast cancer
- (2015) Valentina D’Amato et al. CANCER TREATMENT REVIEWS
- Individualization of tamoxifen therapy: Much more than just CYP2D6 genotyping
- (2015) Lisette Binkhorst et al. CANCER TREATMENT REVIEWS
- Next-Generation Sequencing to Guide Clinical Trials
- (2015) L. L. Siu et al. CLINICAL CANCER RESEARCH
- Effects of Pharmacogenetics on the Pharmacokinetics and Pharmacodynamics of Tamoxifen
- (2015) Aurelia H. M. de Vries Schultink et al. CLINICAL PHARMACOKINETICS
- Targeted therapy in her2-positive metastatic breast cancer: a review of the literature
- (2015) X. Zhu et al. Current Oncology
- Diagnostic associations of gene expression signatures in prostate cancer tissue
- (2015) Hao G. Nguyen et al. CURRENT OPINION IN UROLOGY
- Therapeutic management of ALK+nonsmall cell lung cancer patients
- (2015) Boris Duchemann et al. EUROPEAN RESPIRATORY JOURNAL
- Basket Trials and the Evolution of Clinical Trial Design in an Era of Genomic Medicine
- (2015) Amanda J. Redig et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular Profiling and Targeted Therapy for Advanced Thoracic Malignancies: A Biomarker-Derived, Multiarm, Multihistology Phase II Basket Trial
- (2015) Ariel Lopez-Chavez et al. JOURNAL OF CLINICAL ONCOLOGY
- Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31
- (2015) Karen A. Gelmon et al. JOURNAL OF CLINICAL ONCOLOGY
- Stem cell state and the epithelial-to-mesenchymal transition: Implications for cancer therapy
- (2015) Vera S. Donnenberg et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Immune Checkpoint inhibitors: An introduction to the next-generation cancer immunotherapy
- (2015) Lucy Lee et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Application of Molecular Profiling in Clinical Trials for Advanced Metastatic Cancers
- (2015) S. Kummar et al. JNCI-Journal of the National Cancer Institute
- A Decision Support Framework for Genomically Informed Investigational Cancer Therapy
- (2015) Funda Meric-Bernstam et al. JNCI-Journal of the National Cancer Institute
- Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial
- (2015) Christophe Le Tourneau et al. LANCET ONCOLOGY
- NCI-MATCH pairs tumor mutations with matching drugs
- (2015) Vicki Brower NATURE BIOTECHNOLOGY
- NCI-MATCH trial pushes cancer umbrella trial paradigm
- (2015) Asher Mullard NATURE REVIEWS DRUG DISCOVERY
- Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
- (2015) David M. Hyman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
- (2015) Sandra M. Swain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oncotype DX® colon cancer assay for prediction of recurrence risk in patients with stage II and III colon cancer: A review of the evidence
- (2015) Y. Nancy You et al. SURGICAL ONCOLOGY-OXFORD
- Novel Approaches to Treatment of Advanced Melanoma: A Review on Targeted Therapy and Immunotherapy
- (2015) Anna Niezgoda et al. Biomed Research International
- Application of Molecular Profiling in Clinical Trials for Advanced Metastatic Cancers
- (2015) S. Kummar et al. JNCI-Journal of the National Cancer Institute
- A Decision Support Framework for Genomically Informed Investigational Cancer Therapy
- (2015) Funda Meric-Bernstam et al. JNCI-Journal of the National Cancer Institute
- Human epidermal growth factor receptor 2 positive (HER2+) metastatic breast cancer: how the latest results are improving therapeutic options
- (2015) Hanfang Jiang et al. Therapeutic Advances in Medical Oncology
- Combination Therapies to Inhibit the RAF/MEK/ERK Pathway in Melanoma: We are not Done Yet
- (2015) Grant A. McArthur Frontiers in Oncology
- Trastuzumab emtansine: mechanisms of action and drug resistance
- (2014) Mark Barok et al. BREAST CANCER RESEARCH
- Incorporation of Pharmacogenomics into Routine Clinical Practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline Development Process
- (2014) Kelly Caudle et al. CURRENT DRUG METABOLISM
- Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer
- (2014) Hidemi Kawajiri et al. Expert Review of Anticancer Therapy
- Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial
- (2014) Ian E Krop et al. LANCET ONCOLOGY
- Discovery and saturation analysis of cancer genes across 21 tumour types
- (2014) Michael S. Lawrence et al. NATURE
- Assessing the clinical utility of cancer genomic and proteomic data across tumor types
- (2014) Yuan Yuan et al. NATURE BIOTECHNOLOGY
- Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer
- (2014) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
- (2014) Benjamin J. Solomon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Navigating the Rapids: The Development of Regulated Next-Generation Sequencing-Based Clinical Trial Assays and Companion Diagnostics
- (2014) Saumya Pant et al. Frontiers in Oncology
- Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
- (2013) Antonio C. Wolff et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study
- (2013) J-Y Douillard et al. BRITISH JOURNAL OF CANCER
- Prospective Study of the Effect of the 21-Gene Assay on Adjuvant Clinical Decision-Making in Japanese Women With Estrogen Receptor-Positive, Node-Negative, and Node-Positive Breast Cancer
- (2013) Hideko Yamauchi et al. Clinical Breast Cancer
- CYP2D6 Genotype and Adjuvant Tamoxifen: Meta-Analysis of Heterogeneous Study Populations
- (2013) M A Province et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Clinical Implementation of Germ Line Cancer Pharmacogenetic Variants During the Next-Generation Sequencing Era
- (2013) N K Gillis et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Clinical Pharmacogenetics Implementation Consortium Guidelines for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing
- (2013) K E Caudle et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing: 2013 Update
- (2013) M V Relling et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Afatinib: First Global Approval
- (2013) Rosselle T. Dungo et al. DRUGS
- Genomics-Driven Oncology: Framework for an Emerging Paradigm
- (2013) Levi A. Garraway JOURNAL OF CLINICAL ONCOLOGY
- Biologic Determinants of Tumor Recurrence in Stage II Colon Cancer: Validation Study of the 12-Gene Recurrence Score in Cancer and Leukemia Group B (CALGB) 9581
- (2013) Alan P. Venook et al. JOURNAL OF CLINICAL ONCOLOGY
- Validation of the 12-Gene Colon Cancer Recurrence Score in NSABP C-07 As a Predictor of Recurrence in Patients With Stage II and III Colon Cancer Treated With Fluorouracil and Leucovorin (FU/LV) and FU/LV Plus Oxaliplatin
- (2013) Greg Yothers et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma WithEGFRMutations
- (2013) Lecia V. Sequist et al. JOURNAL OF CLINICAL ONCOLOGY
- Validation and Implementation of Targeted Capture and Sequencing for the Detection of Actionable Mutation, Copy Number Variation, and Gene Rearrangement in Clinical Cancer Specimens
- (2013) Colin C. Pritchard et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing
- (2013) Garrett M Frampton et al. NATURE BIOTECHNOLOGY
- 'Basket studies' will hold intricate data for cancer drug approvals
- (2013) Cassandra Willyard NATURE MEDICINE
- Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
- (2013) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- Can knowledge of germline markers of toxicity optimize dosing and efficacy of cancer therapy?
- (2012) Daniel Crona et al. Biomarkers in Medicine
- CYP2D6 Metabolism and Patient Outcome in the Austrian Breast and Colorectal Cancer Study Group Trial (ABCSG) 8
- (2012) M. P. Goetz et al. CLINICAL CANCER RESEARCH
- Differential Protein Stability and ALK Inhibitor Sensitivity of EML4-ALK Fusion Variants
- (2012) J. M. Heuckmann et al. CLINICAL CANCER RESEARCH
- Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma
- (2012) A. M. Menzies et al. CLINICAL CANCER RESEARCH
- Re: CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women With Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial
- (2012) Y. Nakamura et al. JNCI-Journal of the National Cancer Institute
- CYP2D6 and UGT2B7 Genotype and Risk of Recurrence in Tamoxifen-Treated Breast Cancer Patients
- (2012) James M. Rae et al. JNCI-Journal of the National Cancer Institute
- CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women with Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial
- (2012) Meredith M. Regan et al. JNCI-Journal of the National Cancer Institute
- Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
- (2012) Axel Hauschild et al. LANCET
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
- (2012) Sunil Verma et al. NEW ENGLAND JOURNAL OF MEDICINE
- KLC1-ALK: A Novel Fusion in Lung Cancer Identified Using a Formalin-Fixed Paraffin-Embedded Tissue Only
- (2012) Yuki Togashi et al. PLoS One
- Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement
- (2011) Hye Ryun Kim et al. CANCER
- CH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper Mutant
- (2011) Hiroshi Sakamoto et al. CANCER CELL
- Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing
- (2011) M V Relling et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling
- (2011) Nikhil Wagle et al. JOURNAL OF CLINICAL ONCOLOGY
- Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)
- (2011) Masahiro Fukuoka et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study
- (2011) Kenneth J O'Byrne et al. LANCET ONCOLOGY
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
- (2011) Caicun Zhou et al. LANCET ONCOLOGY
- EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study
- (2011) Robert Pirker et al. LANCET ONCOLOGY
- BRAFMutations in Hairy-Cell Leukemia
- (2011) Enrico Tiacci et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- High-Throughput Detection of Actionable Genomic Alterations in Clinical Tumor Samples by Targeted, Massively Parallel Sequencing
- (2011) Nikhil Wagle et al. Cancer Discovery
- Dose-Dependent Association between UGT1A1*28 Genotype and Irinotecan-Induced Neutropenia: Low Doses Also Increase Risk
- (2010) Z.-Y. Hu et al. CLINICAL CANCER RESEARCH
- Prospective Multicenter Study of the Impact of the 21-Gene Recurrence Score Assay on Medical Oncologist and Patient Adjuvant Breast Cancer Treatment Selection
- (2010) Shelly S. Lo et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Randomized Study Comparing Docetaxel Plus Trastuzumab With Vinorelbine Plus Trastuzumab As First-Line Therapy of Metastatic or Locally Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: The HERNATA Study
- (2010) Michael Andersson et al. JOURNAL OF CLINICAL ONCOLOGY
- COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
- (2010) Cory M. Johannessen et al. NATURE
- Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
- (2010) Ramin Nazarian et al. NATURE
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
- (2010) Makoto Maemondo et al. NEW ENGLAND JOURNAL OF MEDICINE
- KIF5B-ALK, a Novel Fusion Oncokinase Identified by an Immunohistochemistry-based Diagnostic System for ALK-positive Lung Cancer
- (2009) K. Takeuchi et al. CLINICAL CANCER RESEARCH
- I-SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy
- (2009) AD Barker et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- (2009) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Profiling Critical Cancer Gene Mutations in Clinical Tumor Samples
- (2009) Laura E. MacConaill et al. PLoS One
- Lapatinib: A dual inhibitor of human epidermal growth factor receptor tyrosine kinases
- (2008) P MEDINA et al. CLINICAL THERAPEUTICS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started